13
Jun

Amgen is hardly gun shy about high-risk, high-reward R&D bets, but the Big Biotech’s swing-for-the-fences approach to research is bad for the bottom line, according to Bernstein analyst Geoffrey Porges.

…read more

Source: Analyst: Amgen’s moonshot R&D spending is bad for business

    

0 No comments